₹1,486.40
−0.46%NSE close, 16 Nov 2026
+42.69%
Molbio Diagnostics is a small cap company, listed on NSE under the symbol MOLBIO. At ₹1,486.40 a share, the market values the whole company at ₹17,129 crore.
Promoters hold 41.29% of the shares. Foreign institutions hold 1.59%, and domestic institutions, mutual funds among them, 19.08%.
₹ crore. Consolidated figures.
| Line | Jun 2026 | 6M to Sep 2026 |
|---|---|---|
| Sales | 408 | 667 |
| Expenses | 308 | 523 |
| Operating profit | 101 | 145 |
| Operating margin | 24.6% | 21.7% |
| Other income | 3.1 | 8.9 |
| Interest | 10.7 | 19.6 |
| Depreciation | 17.1 | 40.4 |
| Profit before tax |
Transcript of Earnings Call with analysts and investors for the quarter and half year ended on September 30, 2026
Monitoring Agency Report on the utilization of proceeds raised through issuanceof equity shares by way of Public Issue of the Company
Link of Recording of Earnings Call held on November 05,2026 for the quarter and half year ended September30, 2026.
| 93.4 |
| Tax | 23.2 | 33.0 |
|---|
| Net profit | 58.8 | 73.9 |
|---|
| EPS (₹) | 5.21 | 6.52 |
|---|
₹ crore, financial years to March.
Not filed yet.
₹ crore, at each year's end and the latest half year.
| Line | Sep 2026 |
|---|---|
| Shareholders’ equity | 1,440 |
| Borrowings | 352 |
| Total liabilities | 761 |
| Fixed assets | 243 |
| Investments | 0 |
| Cash and equivalents | 493 |
| Total assets | 2,329 |
₹ crore, by financial year, and the latest half year.
| Line | 6M to Sep 2026 |
|---|---|
| From operations | 167 |
| From investing | −141 |
| From financing | 89.6 |
| Spent on fixed assets | −33.6 |
| Free cash flow | 134 |
Margins, returns, debt, tax and cash.
Not filed yet.
The financial results for the period ended September 30, 2026.
Schedule of meet
Significant increase in volume has been observed in Molbio Diagnostics Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written…
Significant increase in volume has been observed in Molbio Diagnostics Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written…
Outcome of Board Meeting held on September 25, 2026 for re-appointment of M/s K. S. Kamalakara & Co, Cost Accountants as the Cost Auditor of the Company for FY 2026-27.
Schedule of meet to be held on Tuesday, September 22, 2026 at 11.00 A.M.(IST) onwards.
Intimation regarding change of Corporate Identification Number (CIN) of the Company.
Investor Presentation on the Unaudited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2026
Press Release for the Quarter ended June 30, 2026
The financial results for the period ended Jun 30, 2026.